Background

Exosomes are endogenous nanovesicles that transfer RNA, proteins, and lipids between cells, a property that underlies their promise as diagnostics and therapeutics 12567. Their cargo loading is guided by RNA‑binding proteins such as hnRNPA2B1, hnRNPK, and hnRNPH1 that recognize specific motifs 1, while chaperone proteins like Hsp70 are transferred to maintain proteostasis 2. Pathological cargoes, including amyloid‑β oligomers and senescence‑associated inflammatory factors, can also be spread via exosomes, contributing to disease propagation 34. Despite this bidirectional capacity, the rules that dictate which tissues internalize a given exosome population remain incompletely understood.

Mechanistic Insight

We hypothesize that the density and pattern of sialic acid residues on exosome surface glycans act as a molecular zip‑code that directs tissue‑specific uptake through interactions with Siglec family receptors. High sialylation favors binding to inhibitory Siglecs on myeloid cells, promoting rapid clearance by the mononuclear phagocyte system, whereas low sialylation reduces Siglec engagement and allows exosomes to linger in circulation and preferentially fuse with neurons or other parenchymal cells. By enzymatically remodeling exosome sialylation—using sialyltransferases or neuraminidase pretreatment—we predict that pathological cargoes (e.g., Alzheimer’s‑associated Aβ oligomers) can be diverted away from vulnerable brain parenchyma toward phagocytic sinks, attenuating downstream toxicity.

Testable Predictions

1. Exosomes isolated from young, healthy donor cells will display higher surface sialic acid levels than those from senescent or Alzheimer’s‑affected cells, correlating with reduced neuronal uptake in vitro.
2. Enzymatic desialylation of exosomes carrying fluorescently labeled Aβ oligomers will increase their colocalization with primary cultured neurons by >2‑fold compared with untreated vesicles.
3. In vivo injection of sialyl‑enriched exosomes into APP/PS1 mice will decrease brain Aβ burden and improve cognitive performance relative to controls receiving untreated exosomes.

Experimental Approach

First, produce exosomes from HEK293T cells transfected with plasmids encoding either ST6GAL1 (α‑2,6‑sialyltransferase) or a cytosolic neuraminidase (NEU1) to generate sialyl‑high and sialyl‑low populations, respectively. Validate surface sialic acid density using lectin blotting with SNA (specific for α‑2,6‑sialic acid) and flow cytometry with fluorescently labeled SNA. Next, load these exosomes with a uniform cargo—either synthetic miRNA‑124 or recombinant Aβ₁₋₄₂ oligomers—using electroporation or sonication, ensuring equivalent cargo amounts across conditions. Assess uptake in primary mouse neurons and microglial cultures via confocal microscopy and quantify internalized cargo by fluorescence intensity or ELISA. Finally, evaluate biodistribution and therapeutic efficacy in APP/PS1 mice after intravenous injection, measuring brain amyloid load (6E10 immunostaining), microglial activation (Iba1), and behavior (Morris water maze).

Potential Impact

If validated, this hypothesis would reveal a simple post‑production modification—glycan sialylation—that controls exosome biodistribution without altering their protein or lipid core. It would provide a universal strategy to detoxify pathogenic exosome cargoes, improve the safety of exosome‑based therapeutics, and inspire diagnostic assays that read exosome sialylation patterns as biomarkers of disease state or tissue‑specific exposure.